Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Topo-guided LASIK and Photorefractive Keratectomy vs Wavefront LASIK and Photorefractive Keratectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03075176
Recruitment Status : Recruiting
First Posted : March 9, 2017
Last Update Posted : May 6, 2021
Sponsor:
Information provided by (Responsible Party):
Mark Mifflin, University of Utah

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study evaluates the difference in results between eyes that have been treated wavefront optimized laser vision correction (either LASIK or Photorefractive Keratectomy) compared to eyes treated with topography-guided laser vision correction (either LASIK or Photorefractive Keratectomy). Each participant will receive wavefront optimized correction in one eye and topography-guided correction in the other.

Condition or disease Intervention/treatment Phase
Surgery Myopia Device: Wavefront optimized LASIK Device: Wavefront optimized Photorefractive Keratectomy Device: Topography-guided LASIK Device: Topography-guided Photorefractive Keratectomy Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Each participant will receive wavefront optimized surgery in one eye and topography-guided surgery in the second eye.
Masking: Single (Participant)
Masking Description: Participants will be masked as to which type of surgery they receive in either eye.
Primary Purpose: Treatment
Official Title: Outcomes of Topography-guided LASIK and Photorefractive Keratectomy Compared to Wavefront Optimized LASIK and Photorefractive Keratectomy
Actual Study Start Date : February 13, 2017
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : June 30, 2022

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Wavefront optimized LASIK Device: Wavefront optimized LASIK
Wavefront optimized laser vision correction

Device: Topography-guided LASIK
Topography-guided laser vision correction
Active Comparator: Wavefront optimized Photorefractive Keratectomy Device: Wavefront optimized Photorefractive Keratectomy
Wavefront optimized laser vision correction

Device: Topography-guided Photorefractive Keratectomy
Topography-guided laser vision correction
Active Comparator: Topography-guided LASIK Device: Wavefront optimized LASIK
Wavefront optimized laser vision correction

Device: Topography-guided LASIK
Topography-guided laser vision correction
Active Comparator: Topography-guided Photorefractive Keratectomy Device: Wavefront optimized Photorefractive Keratectomy
Wavefront optimized laser vision correction

Device: Topography-guided Photorefractive Keratectomy
Topography-guided laser vision correction


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change in uncorrected visual acuity from baseline to month 12 [ Time Frame: 12 months ]
    Uncorrected visual acuity will be tested pre-operatively through month 12


Secondary Outcome Measures :
  1. Change in contrast sensitivity from baseline to month 3 [ Time Frame: 3 months ]
    Contrast sensitivity will be tested pre-operatively and 3 months post-operatively


Other Outcome Measures:
  1. Change in degree of higher order aberrations from baseline to 3 months [ Time Frame: 3 months ]
    Aberrometry measurements will be taken pre-operatively and 3 months post surgery

  2. Change in quality of life score from baseline to 3 months [ Time Frame: 3 months ]
    The validated Quality of Life Impact of Refractive Correction survey will be administered pre-operatively and 3 months post surgery


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All subjects who are deemed suitable candidates for laser refractive surgery after routine refractive surgery screening will be considered eligible for participation in this study.

Subjects must be at least 21 years of age and not pregnant or nursing (due to fluctuations in visual parameters during pregnancy)

Exclusion Criteria:

  • Any patient who is not a suitable candidate for LASIK or PRK will not be included.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03075176


Contacts
Layout table for location contacts
Contact: Mark Mifflin, MD 801-585-3937 mark.mifflin@hsc.utah.edu
Contact: Myrna Church 801-585-3937 Myrna.Church@hsc.utah.edu

Locations
Layout table for location information
United States, Utah
Moran Eye Center - Midvalley Location Recruiting
Murray, Utah, United States, 84107
Contact: Mark Mifflin, MD    801-583-3447    Mark.Mifflin@hsc.utah.edu   
Sponsors and Collaborators
University of Utah
Investigators
Layout table for investigator information
Principal Investigator: Mark Mifflin, MD University of Utah Moran Eye Center
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Mark Mifflin, Professor, Ophthalmology/Visual Sciences, University of Utah
ClinicalTrials.gov Identifier: NCT03075176    
Other Study ID Numbers: IRB # 95434
First Posted: March 9, 2017    Key Record Dates
Last Update Posted: May 6, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Mark Mifflin, University of Utah:
Photorefractive keratectomy
Laser-assisted in situ keratomileusis
Additional relevant MeSH terms:
Layout table for MeSH terms
Myopia
Refractive Errors
Eye Diseases